MORBIUS: The Living Vampire's Big Screen Debut Has Somehow Swooped To #1 On Apple TV

Despite being met with negative critical reviews and ridicule from some fans, Morbius has managed to take a bite out of the competition by heading straight to #1 in the Apple TV charts. Read on for more!

Morbius was met by overwhelmingly negative reviews back in April, and even now, it sits at a lowly 17% on Rotten Tomatoes. Comic book fans were unimpressed for the most part, but there were those who had fun with the Living Vampire's live-action debut (and Matt Smith's madcap performance).

That might explain this news. As you can see below, Morbius has swooped straight to the top of the Apple TV charts, an indication that people have rushed to buy and rent the blockbuster on Digital. 

There could be any number of reasons for this. Morbid curiosity is one, though we'd guess that as well as the die-hard Marvel fans who did enjoy Morbius, there are also those who missed it in theaters. It only grossed $163.1 million at the worldwide box office, so compared to Venom ($856.1 million) and Venom: Let There Be Carnage ($506.9 million), a lot of people didn't see this one on the big screen.

"Jared Leto’s transformation makes for compelling viewing," we said in our review back in March, "but the Living Vampire can’t elevate a disappointing story that serves as a powerful, dare we say terrifying, reminder that Spider-Man is better off (and safer) in the MCU with Marvel Studios."

Morbius is available on Digital now and will hit 4K Ultra HD, Blu-ray and DVD on June 14.

DISCLAIMER: Comic Book Movie is protected from liability under the DMCA (Digital Millenium Copyright Act) and "Safe Harbor" provisions. This post was submitted by a volunteer contributor who has agreed to our Terms of Service. Comic Book Movie will disable users who knowingly commit plagiarism, piracy, trademark or copyright infringement. Please contact us for expeditious removal of copyrighted/trademarked content. Learn more about our copyright and trademark policies HERE.